indazoles has been researched along with Fatigue in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (6.06) | 29.6817 |
| 2010's | 27 (81.82) | 24.3611 |
| 2020's | 4 (12.12) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, JN; Hammond, JM; Lee, S; Sneed, GT | 1 |
| Cao, X; Gao, W; Jin, L; Poole, A; Ratto, B; Ravichandran, S; Swallow, E; Tang, D; Vogelzang, NJ | 1 |
| de Geeter, P; Goebell, PJ; Grünwald, V; Herrmann, E; Hogrefe, C; Marschner, N; Merling, M; Panic, A; Potthoff, K; Staehler, M; Vannier, C | 1 |
| Alameh, IA; Assi, HI; Charafeddine, M; Farhat, F; Halim, NA; Karak, FE; Khoury, J; Nakib, CE; Sayed, RE; Zerdan, MB | 1 |
| Bondarenko, A; Borisov, P; Tishova, Y; Tsimafeyeu, I; Zakurdaeva, K; Zukov, R | 1 |
| Dinkic, C; Eichbaum, M; Fricke, HC; Gebauer, G; Grischke, EM; Lenz, F; Marme, F; Rom, J; Schmidt, M; Schneeweiss, A; Sohn, C; Wallwiener, M | 1 |
| Gu, J; Li, J | 1 |
| Gunderson, CC; Matulonis, U; Moore, KN | 1 |
| Adjei, AA; Bishop, WR; Carr, D; Chun, P; Cooper, A; Dayananth, P; Deng, Y; Flaherty, KT; Fong, PC; Hwu, WJ; Kirschmeier, P; Long, BJ; Miselis, NR; Moreno, BH; Moschos, SJ; Ramanathan, RK; Ribas, A; Robert, L; Rubin, EH; Rubino, J; Rush, TS; Samatar, AA; Schiller, J; Shapira-Frommer, R; Shipps, GW; Sullivan, RJ; Tawbi, HA; Zhang, D | 1 |
| O'Cearbhaill, RE | 1 |
| Cao, Z; Deng, H; Hong, Z; Huang, Y; Wei, Y; Yuan, X; Zhang, W | 1 |
| Arnaldi, G; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Massari, F; Procopio, G; Rizzo, M; Santoni, M; Tortora, G; Trementino, L | 1 |
| Antonysamy, MA; Bliss, RL; Dudek, AZ; Fischer, JH; Ganesan, C; Jha, G; Obulareddy, SJ | 1 |
| Chiu, YL; LoRusso, P; Ricker, JL; Xiong, H | 1 |
| Ledoux, B; Petit, B; Seront, E; van Marcke, C | 1 |
| Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C | 1 |
| Keck, B; Lieb, V; Lüdecke, G; Sikic, D | 1 |
| Hata, H; Imafuku, K; Inamura, Y; Kitamura, S; Shimizu, H; Yanagi, T; Yoshino, K | 1 |
| Aggarwal, R; Bartelink, I; Cripps, A; Grabowsky, J; Harb, A; Jahan, T; Leng, J; Mastroserio, I; Munster, PN; Pawlowska, N; Reinert, A; Ryan, CJ; Thomas, S; Truong, TG | 1 |
| Dowlati, A; Gibson, DM; Hodge, JP; Hurwitz, HI; Merkle, EM; Pandite, L; Saini, S; Savage, S; Suttle, AB | 1 |
| Chen, CS; Goh, BC; Gupta, N; Hartono, S; Humerickhouse, R; Koh, TS; Lee, SC; Lim, R; Lim, SE; McKeegan, E; Ong, AB; Pradhan, R; Soo, R; Steinberg, J; Sukri, N; Thng, CH; Wong, CI; Wong, J; Yong, WP | 1 |
| Hashimoto, J; Itoh, K; Minami, H; Mukai, H; Mukohara, T; Nagai, S; Nakajima, H; Umeyama, Y | 1 |
| Altorki, N; Bauer, T; Felip, E; Grannis, FW; Guarino, MJ; Gurpide, A; Huff, A; Lane, ME; Lee, PC; Mitchell, JD; Ottesen, LH; Pass, H; Peylan-Ramu, N; Reeves, A; Roychowdhury, DF; Swann, RS; Tachdjian, S; Yankelevitz, DF | 1 |
| Arumugham, T; Chiorean, EG; Dar, MM; Forman, K; Gainer, SD; Heath, EI; Hodge, JP; Lager, JJ; LoRusso, P; Malburg, L; Suttle, AB; Sweeney, CJ | 1 |
| Chayahara, N; Fujiwara, Y; Kiyota, N; Minami, H; Mukohara, T; Suzuki, A; Umeyama, Y | 1 |
| Chowbay, B; Gao, F; Goh, BC; Ivy, P; Koh, TS; Leong, SS; Lim, WT; Ng, QS; Singh, O; Tan, DS; Tan, EH; Thng, CH; Toh, CK | 1 |
| Joly, F | 1 |
| Chatta, G; Hussain, M; Karrison, T; O'Donnell, PH; Posadas, EM; Shevrin, D; Stadler, WM; Szmulewitz, RZ; Ward, JE | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C | 1 |
| Chen, Y; Garrett, M; Hee, B; Klamerus, KJ; LaBadie, RR; Mount, J; Ni, G; Pithavala, YK; Selaru, P; Toh, M; Tortorici, MA | 1 |
| Ansell, P; Carlson, DM; Carr, BI; Chen, PJ; Dowell, B; Gill, S; Knox, JJ; McKeegan, EM; Pedersen, M; Qian, J; Qin, Q; Ricker, JL; Scappaticci, FA; Toh, HC; Yong, WP | 1 |
| Andrews, L; Fishman, M; Gorbunova, V; Jonasch, E; Larkin, J; Negrier, S; Olivier, K; Pyle, L; Staehler, M; Wood, L | 1 |
8 review(s) available for indazoles and Fatigue
| Article | Year |
|---|---|
The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Fatigue; Humans; Hypertension; Indazoles; Kidney Neoplasms; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2019 |
Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.
Topics: Anilides; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Neoplasms; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Receptors, Vascular Endothelial Growth Factor | 2017 |
Management of the toxicities of common targeted therapeutics for gynecologic cancers.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Autoimmune Diseases; Bevacizumab; Diarrhea; Epistaxis; Fatigue; Female; Genital Neoplasms, Female; Headache; Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Perforation; Molecular Targeted Therapy; Nausea; Neutropenia; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Proteinuria; Pyrimidines; Risk Assessment; Sulfonamides; Vomiting; Water-Electrolyte Imbalance | 2018 |
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatigue; Health Care Costs; Humans; Indazoles; Kidney Neoplasms; Liver; Middle Aged; Neutropenia; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome | 2019 |
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Incidence; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Risk; Sorafenib; Sulfonamides; Sunitinib | 2015 |
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2016 |
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib | 2016 |
[Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Fatigue; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Sunitinib | 2011 |
17 trial(s) available for indazoles and Fatigue
| Article | Year |
|---|---|
First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diarrhea; Fatigue; Female; Humans; Hypothyroidism; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome | 2021 |
Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Phase 2 Randomized Study FARETES.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatigue; Follow-Up Studies; Humans; Hypogonadism; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Quality of Life; Sulfonamides; Sunitinib; Testosterone | 2021 |
Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Indazoles; Leukopenia; Liver Function Tests; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Pyrimidines; Sulfonamides | 2017 |
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Animals; Biological Availability; Cell Line, Tumor; Diarrhea; Dogs; Dose-Response Relationship, Drug; Drug Eruptions; Drug Evaluation, Preclinical; Fatigue; Female; Humans; Indazoles; Male; MAP Kinase Signaling System; Maximum Tolerated Dose; Mice; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nausea; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Rats; Triazoles; Xenograft Model Antitumor Assays; Young Adult | 2018 |
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytokines; Disease-Free Survival; E-Selectin; Epothilones; Fatigue; Female; Humans; Indazoles; Male; Middle Aged; Neoplasms; Neutropenia; Pyrimidines; Retreatment; Sulfonamides; Survival Rate; Thrombocytopenia | 2016 |
Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Circadian Rhythm; Cross-Over Studies; Drug Administration Schedule; Fatigue; Female; Food-Drug Interactions; Half-Life; Hand-Foot Syndrome; Humans; Hypertension; Indazoles; Male; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index | 2014 |
Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
Topics: Acetylation; Adult; Aged; Alanine Transaminase; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Benzofurans; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Drug Resistance; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fatigue; Female; Gene Expression; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pyrimidines; Sulfonamides; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2017 |
Phase I trial of pazopanib in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Anorexia; Cohort Studies; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Hypertension; Indazoles; Male; Middle Aged; Nausea; Neoplasms; Pyrimidines; Sulfonamides; Vomiting | 2009 |
Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Hypertension; Indazoles; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Axitinib; Biomarkers; Fatigue; Female; Humans; Hypertension; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Thyrotropin; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Fatigue; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypertension; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrimidines; Sulfonamides; Treatment Outcome | 2010 |
A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Cohort Studies; Cross-Over Studies; Dietary Fats; Fatigue; Female; Food-Drug Interactions; Humans; Hypertension; Indazoles; Male; Middle Aged; Neoplasms; Pyrimidines; Sulfonamides | 2010 |
Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Asian People; Axitinib; Biomarkers; Fatigue; Female; Humans; Hyperthyroidism; Hypothyroidism; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-kit; Thyroglobulin; Thyrotropin; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2012 |
A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anorexia; Asian People; Carcinoma; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrimidines; Sulfonamides; Treatment Outcome; Vomiting | 2011 |
A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.
Topics: Antineoplastic Agents; Chicago; Diarrhea; Early Termination of Clinical Trials; Fatigue; Humans; Indazoles; Male; Orchiectomy; Patient Compliance; Prostatic Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome; United States; United States Department of Defense; Universities | 2012 |
Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.
Topics: Adult; Aged; Axitinib; Cross-Over Studies; Diarrhea; Dietary Fats; Energy Intake; Fasting; Fatigue; Female; Food-Drug Interactions; Humans; Imidazoles; Indazoles; Male; Middle Aged; Nausea; Tablets; Young Adult | 2012 |
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Indazoles; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Phenylurea Compounds; Treatment Outcome; Tumor Burden; Young Adult | 2013 |
8 other study(ies) available for indazoles and Fatigue
| Article | Year |
|---|---|
Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Diarrhea; Fatigue; Female; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Time Factors | 2020 |
Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
Topics: Adult; Aged; Appetite; Fatigue; Female; Humans; Indazoles; Lebanon; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Tertiary Care Centers; Young Adult | 2021 |
Using PARP Inhibitors in Advanced Ovarian Cancer.
Topics: Anemia; Creatinine; Drug Administration Schedule; Drug Interactions; Exanthema; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Heart Rate; Humans; Hypertension; Indazoles; Leukopenia; Mutation; Myelodysplastic Syndromes; Nasopharyngitis; Nausea; Ovarian Neoplasms; Piperidines; Pneumonia; Poly(ADP-ribose) Polymerase Inhibitors; Thrombocytopenia; Transaminases; Vomiting | 2018 |
Rapid and fatal acute heart failure induced by pazopanib.
Topics: Antineoplastic Agents; Dyspnea; Fatal Outcome; Fatigue; Female; Heart Failure; Humans; Indazoles; Middle Aged; Pyrimidines; Sarcoma, Synovial; Sulfonamides; Thoracic Neoplasms | 2015 |
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Pazopanib does not bring remarkable improvement in patients with angiosarcoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Chemical and Drug Induced Liver Injury; Disease-Free Survival; Fatigue; Female; Hemangiosarcoma; Humans; Indazoles; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2017 |
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult | 2012 |
Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes.
Topics: Axitinib; Carcinoma, Renal Cell; Diarrhea; Dysphonia; Fatigue; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Nausea; Protein Kinase Inhibitors; Proteinuria; Vomiting | 2014 |